Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Chihiro Fushimi

Citation

Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252

Authors

C. Fushimi1, D. Kawakita2, H. Takahashi1, T. Nagao3, H. Hirai3, N. Saigusa3, T. Masubuchi4, T. Matsuki4, T. Okada4, D. Baba4, K. Miura4, T. Saotome5, Y. Tada4

Author affiliations

  • 1 Department Of Head And Neck Oncology And Surgery, International University of Health and Welfare Mita Hospital, 108-8329 - Tokyo/JP
  • 2 Department Of Otorhinolaryngology, Head And Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya/JP
  • 3 Department Of Anatomic Pathology, Tokyo Medical University School of Medicine, Tokyo/JP
  • 4 Department Of Head And Neck Oncology And Surgery, International University of Health and Welfare Mita Hospital, Tokyo/JP
  • 5 Division Of Medical Oncology, Matsudo City General Hospital, Matsudo/JP
More

Resources

Abstract 5848

Background

A phase II trial of combined androgen blockade (CAB) in patients with advanced androgen receptor (AR)–positive salivary gland carcinoma (SGC) showed 40% of the overall response rate. However, biomarkers which predict survival in this population remain unknown.

Methods

A total of 99 patients with AR–positive SGC treated with leuprorelin acetate plus bicalutamide were included. Age, sex, ECOG performance status (PS), previous treatment with trastuzumab plus docetaxel, modified Glasgow Prognosis Score (mGPS), neutrocyte-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), serum C-reactive protein (CRP) and testosterone level, HER2 status (according to ASCO/CAP Guidelines), mutational status of BRAF, PIK3CA, HRAS, AKT1 and TP53, immunohistochemistry (IHC) score of AR, Ki-67, CK5/6, p53, HER3, Akt, PI3K, FOXA1, adipophilin, mTOR and PTEN were assessed and correlated with progression-free survival (PFS) and overall survival (OS).

Results

Female sex, mGPS (1 or 2 vs. 0), NLR (≥4.48), PLR (≥234.27), and Ki-67 labeling index (≥ 40%) were significantly associated with shorter PFS (hazard ratio [HR], 3.57, 2.01, 1.76, 1.62, and 2.16, respectively) and OS (HR, 4.91, 4.98, 3.10, 2.95, and 1.78, respectively). IHC scores of PTEN (3+) and adipophilin (≥5%) were related with favorable PFS (HR, 0.57 and 0.49, respectively) and OS (HR, 0.48 and 0.42, respectively). Age, ECOG PS, CRP, testosterone, AR positive ratio (≥70% or < 70%), HER2 status, previous treatment with trastuzumab plus docetaxel, FOXA1 immunopositivity, and mutational status of BRAF, PIK3CA, HRAS, and TP53 did not have significant association with survival.

Conclusions

Rather than age and PS, sex and higher inflammation-based prognostic scores can serve as predictive biomarkers in patients with advanced SGC treated with CAB. IHC assessment of Ki-67, PTEN, and adipophilin may predict survival of this population. Biological validation of such markers is warranted.

Clinical trial identification

UMIN000009437, Released on 03/12/2012.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

MEXT/JSPS.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings